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Diuretics have long been used to lower blood pressure in hypertensive patients or to control body fluid and electrolyte
homeostasis in diseases such as congestive heart failure, chronic renal failure or cirrhosis. The initial response to diuretics is
a negative sodium and fluid balance. The diuretic-induced loss of salt and water activates several hormonal systems such as
vasopressin, the renin-angiotensin-aldosterone system or the sympathetic nervous system which tend to compensate for the
changes in sodium and water balance. This neurohormonal response may have important clinical implications. Thus, the
activation of the renin-angiotensin-aldosterone cascade appears to be partially responsible for the flat dose-blood pressure
response curve of thiazides in hypertensive patients. It may also be responsible for the difference between responders and
non-responders to diuretic therapy and for the development of side-effects such as hypokalaemia, metabolic alkalosis or
hyponatraemia. There are several ways to prevent the undesirable consequences of the neurohormonal responses to
diuretics. The first is to use low doses of these agents. It is also possible to combine them with agents that block the activity of
the renin-angiotensin-aldosterone system such as A CE inhibitors or in combination with drugs that reduce aldosterone
secretion such as calcium antagonists. The development of drugs able to enhance urinary sodium excretion and to reduce
simultaneously the activity of the renin-angiotensin-aldosterone system may offer a new interesting alternative. This might
perhaps be achieved in the future with the administration of neutral endopeptidase inhibitors which interfere with the
enzymatic degradation of atrial natriuretic peptide.
Introduction
Diuretics have been used for several decades to lower
blood pressure in hypertensive patients or to control
sodium and volume balance in diseases such as congestive
heart failure, chronic renal failure or liver cirrhosis. The
changes in systemic haemodynamics and the modifi-
cations of fluid and electrolyte excretion induced by the
acute or chronic administration of diuretics have been
well characterized'1-21. The initial response to diuretic
therapy is a negative sodium and fluid balance, followed
by a decrease in plasma volume and cardiac output lead-
ing to a fall in blood pressure. The acute reduction in
blood pressure is associated with a compensatory rise in
calculated peripheral vascular resistance.
During long-term diuretic treatment, however, extra-
cellular fluid, plasma volumes and cardiac output tend
to return to control values, whereas peripheral vascular
resistance decreases'31. Blood pressure therefore remains
low despite the normalization of cardiac output. The
mechanisms whereby peripheral vascular resistance is
reduced during prolonged diuretic administration are still
not completely understood. The vasodilating effect of
diuretics may be mediated directly by a reduction in
vascular reactivity to vasoconstrictor mechanisms due to
a decrease in intracellular sodium and calcium concen-
trations in vascular smooth muscle cells'41. This would also
result in a decrease in vascular responsiveness to vasocon-
trictor agents such as angiotensin II or catecholamines'4'51.
Diuretics may also promote the synthesis of vasodilating
hormones such as prostaglandins or kallikreins141.
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The diuretic-induced salt and water loss activates
several neurohormonal systems normally involved in the
regulation of body fluid and electrolyte balance. Depend-
ing on the diuretic dosage, a series of counterregulatory
mechanisms will be triggered which will tend to offset the
benefits of these agents. These include an activation of
the renin-angiotensin-aldosterone system, vasopressin,
prostaglandins and the sympathetic nervous system. This
hormonal response has important clinical consequences
as it modulates the haemodynamic and renal effects of
diuretics. Moreover, it may be responsible for the
development of side-effects. The purpose of this review
is to discuss the consequences of the neurohormonal
response to diuretic therapy and to analyse the different
possibilities to prevent them in various cardiovascular
syndromes.
Physiological regulation of body fluid and electrolyte
balance
The kidneys are responsible for the regulation of salt
and water balance and hence contribute to blood pressure
maintenance. Several neurohormonal systems participate
in this homeostatic process by modulating renal sodium
and water handling and by eliciting systemic and renal
haemodynamic changes. Thus, the sympathetic nervous
system promotes renal sodium reabsorption in the renal
proximal tubule and increases the systemic blood pressure
via the vasoconstrictor properties of norepinephrine.
Furthermore, humoral factors such as renin via angio-
tensin II and aldosterone increase sodium reabsorption in
the proximal and distal tubules. Angiotensin II is also a
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strong vasoconstrictor which plays a major role in the
regulation of glomerular filtration rate. Angiotensin II
increases both the efferent and afferent arteriolar vascular
resistance and thereby controls the glomerular capillary
hydrostatic pressure161. Angiotensin II also reduces the
glomerular ultrafiltration coefficient and the effective
glomerular surface area16"81. Another important humoral
factor is vasopressin whose osmotic and non-osmotic
release allows control of renal water excretion in response
to changes in sodium and water homeostasis. Vasopressin
also exhibits a strong vasopressor potential.
The effect of these vasoconstrictor and salt and water
retaining hormones is generally opposed by that of
vasodepressor and natriuretic hormones such as prostag-
landins, kinines or atrial natriuretic peptide. Atrial
natriuretic peptide (ANP) effectively antagonizes the
renin-angiotensin system. Indeed, ANP decreases renin
secretion, increases urinary sodium and water excretion
and lowers blood pressure'9'101. It also inhibits angiotensin
II-induced vasoconstriction. Moreover, ANP favours the
shift of fluid out of the intravascular compartment which
is reflected by increasing haematocrit1'21. Thus, there is a
multifactorial control system which guarantees water and
sodium balance and blood pressure maintenance. In such
a system not all components have the same weight, and
the development of specific antagonists has facilitated the
determination of the relative contribution of each of these
systems.
NEUROHORMONAL RESPONSE TO SALT DEPLETION
Diuretics enhance renal sodium excretion at different
sites along the renal tubules, and the renin-angiotensin
system plays a major role in the maintenance of sodium
balance. A close relationship exists between a reduction in
sodium balance induced by salt depletion or diuretics and
the response of renin secretion"3141. When human subjects
or animals are changed to a low sodium diet, a rapid
stimulation of the renin-angiotensin system reduces
urinary sodium excretion and maintains circulatory
homeostasis. Indeed, salt-depleted animals pretreated
with a converting-enzyme inhibitor are unable to prevent
renal sodium loss and maintain an adequate blood
pressure1151. A similar observation has been made in
human subjects salt-depleted by a low sodium diet
(10 mmol sodium/day) for 6 days together with a diuretic
on the initial two days and infused with the angiotensin II
antagonist, saralasin1'6'. Saralasin had no effect on blood
pressure in the supine position, but these subjects became
severely hypotensive upon assuming an upright position.
All had accumulated sodium losses over the 6 days
exceeding 200 mmol1161.
The crucial role of the renin-angiotensin system in
titrating sodium excretion has also been shown by the
studies of Hall et a/.'171 who varied sodium intake over a
wide range in three groups of dogs: one control, one with a
fixed, low dose infusion of angiotensin II and one which
converting enzyme was inhibited. All three groups of
animals were able to raise their urinary sodium excretion
in response to the enhanced sodium intake. However,
only the control group could do it without a marked
change in mean arterial pressure. These experiments
demonstrate that whenever the activity of the renin-
angiotensin system is fixed, at a high or at a low level,
major changes in blood pressure are needed to adapt
sodium excretion to salt intake.
In fact, the neurohormonal response to salt depletion
or diuretics, and in particular the renin-response, may
sometimes be such that blood pressure increases or fails
to decrease. This phenomenon has been reported in
patients with congestive heart failure in whom a transient
increase in blood pressure has been found after acute
administration of furosemide1181.
NEUROHORMONAL RESPONSE TO CHANGES IN WATER
BALANCE
The second important property of diuretics is to
increase fluid excretion. The polypeptide hormone, vaso-
pressin, has long been known to exert an antidiuretic
effect and to have a direct vasoconstrictor action on the
arterioles of the peripheral circulation. The results of
several animal studies have suggested a significant role for
vasopressin in maintaining blood pressure during volume
depletion. In these experiments, specific vasopressin
pressor antagonists, which are synthetic analogues acting
as competitive inhibitors of vasopressin at the vascular
(VI) receptor, were used'19"2'1. In our laboratory, we
attempted to evaluate the respective role of vasopressin
and the renin angiotensin system in maintaining blood
pressure during water deprivation12'1. For this purpose,
two groups of rats were water-deprived for 48 h. One
group was pretreated with an ACE inhibitor, to prevent
angiotensin II generation and the other vehicle-treated
group served as control. Following 48 h dehydration,
animals with an intact renin angiotensin system exhibited
a blood pressure of 132 mmHg compared with 105 mmHg
for the group of rats with virtually no circulating angio-
tensin II. Plasma vasopressin levels were increased seven-
fold after 48 h dehydration. Nevertheless, the vascular
antagonist of vasopressin reduced blood pressure by a mere
6 mmHg in the presence of an intact renin angiotensin
system. In contrast, in the absence of angiotensin II, a
marked decrease in blood pressure ( -17 mmHg) was ob-
served after administration of the vasopressin antagonist.
These results suggest that when water deprivation
becomes severe enough to threaten volume homeostasis
and thereby normal blood pressure control, the compen-
satory rise in renin secretion becomes the predominant
factor in blood pressure regulation. Only when the renin
angiotensin system is blocked does vasopressin exert a
greater effect. This supports the idea that a hierarchy
exists among the different compensatory mechanisms.
Taken together, these observations also demonstrate
that among the various neurohormonal factors physio-
logically involved in the response to changes in sodium
and water intake or excretion, the reactivity of the renin
angiotensin system plays a leading role in maintaining
blood pressure within physiologically acceptable limits.
For the clinician, this response will be particularly
important when pharmacological interventions such as
the administration of diuretics or other antihypertensive
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Figure 1 Variations in blood pressure in 257 patients with essential
hypertension treated for 4 weeks with increasing doses of bendro-
fluazide. • = systolic blood pressure; D = diastolic blood pressure.
(Adapted from Carlsen el a/.1231).
agents, are used to lower blood pressure in hyperten-
sive patients or to increase urinary sodium and water
excretion in diseases associated with sodium retention.
NEUROHORMONAL RESPONSE TO DIURETICS IN
HYPERTENSION
Diuretics have long been established as first-line anti-
hypertensive therapy. The blood pressure reduction
obtained with the various types of diuretics is quite com-
parable, although under certain circumstances diuretics
with a very rapid and short-lasting effect, such as the loop
diuretic furosemide, tend to be less effective. Most of the
antihypertensive effect of thiazide- or potassium-sparing
diuretics can be achieved with relatively low doses'22"241.
Figure 1 presents the changes in systolic and diastolic
blood pressure obtained in a recent study with increasing
doses of the thiazide diuretic, bendrofluazide123'. The
diuretic was administered to 257 patients with mild to
moderate hypertension for 12 weeks after a 6 week pla-
cebo period. After 4 weeks of treatment, the maximal
reduction of blood pressure was achieved with 2-5 mg
only. Higher doses caused more pronounced adverse
biochemical effects including deterioration of patients
lipid profile. A similar observation has been made by
Jeunemaitre el a/.|24) who analysed the results obtained
in 182 patients treated with spironolactone alone during
a mean follow-up period of 23 months. The maximal
decrease in diastolic blood pressure was seen with doses
ranging around 75 mg . day"1. However, the incidence of
gynecomastia increased progressively to exceed 50% at
the highest dose of spironolactone used, whereas this side-
effect occurred infrequently at the optimal therapeutic
range, i.e. < 75 mg . day"1.
The neurohormonal response to diuretic therapy may
be partially responsible for this apparently flat dose-
response curve. The regulatory mechanisms seem to vary
from person to person. If some hypertensive subjects do
not respond to diuretics with a fall in blood pressure, it
may be due to a more vigorous angiotensin II-induced
vasoconstriction in these patients. To support this
hypothesis, several investigators have shown that non-
responders to diuretics frequently exhibit higher plasma
renin values and exaggerated aldosterone secretion com-
pared with patients who respond well'25141. Moreover,
during severe sodium restriction i.e. in the presence of
an activated renin angiotensin system, thiazides lack
any substantial additional effect on blood pressure1261.
Furthermore, administration of an angiotensin II antag-
onist or of an angiotensin converting enzyme inhibitor
has been shown to potentiate the hypotensive effects of
diuretics'27*28'. In heart failure patients, enalapril has been
reported to abolish the increases in plasma angiotensin II
and aldosterone normally observed after furosemide,
and to attenuate the rise in plasma catecholamines'29'.
However, the potentiation of the diuretic and natriuretic
effects of diuretics by ACE inhibitors are observed only
if glomerular filtration rate remains stable; a signifi-
cant reduction in glomerular filtration rate may indeed
completely blunt the renal effects of both drugs'29'30'
Consequences of the neurohormonal response to diuretics
The compensatory activation of counter-regulatory
mechanisms has several clinical implications, beside the
fact that they limit the hypotensive response of drugs. In
the case of diuretics, the renin response is also the source
of side-effects. Thus, hypokalaemia and metabolic alkalo-
sis develop in response to aldosterone secretion as more
sodium is presented to the distal tubule, where it is
exchanged for potassium and hydrogen. Hyperuricaemia
frequently occurs as a consequence of the increased renal
proximal reabsorption which compensates for the sodium
losses.
Blood pressure control is an important factor in
reversing left ventricular hypertrophy, but not all anti-
hypertensive agents induce regression of left ventricular
hypertrophy despite adequate control of blood pressure.
It has been postulated that reflex sympathetic stimulation
and activation of the renin angiotensin system may be
responsible for maintaining hypertrophy in the face of
reduced systemic blood pressure. There is increasing
evidence that vasoconstrictive substances, such as angio-
tensin II, vasopressin, catecholamines or endothelin act
as growth promoters and favour the development of
hypertrophy or hyperplasia in vitro'31'. In contrast, vaso-
dilatory substances, such as atrial natriuretic peptide or
prostaglandins, exert growth inhibitory effects.
Reversal of left ventricular hypertrophy during diuretic
therapy has been extensively studied and reviewed'32'. A
reduction in left ventricular mass during diuretic therapy
has been found in six studies but little or no effect of these
agents on ventricular hypertrophy in five reports. As
discussed above, the neurohormonal response to diuretic
treatment may have played a role in the lack of regression
of left ventricular hypertrophy either directly via a growth
promoter effect of angiotensin II, vasopressin and nor-
epinephrine or indirectly by blunting the blood pressure
fall. Interestingly, a regression of hypertrophied cardiac
muscle was almost always obtained when diuretics were
combined with sympatholytic agents such as methyldopa
or alpha-adrenergic blockers, or with beta-blockers,
which, in addition, inhibit renin secretion'32'.
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Neurohormonal response to diuretics in sodium retaining
states
Diuretics are commonly used to increase renal sodium
and water excretion in diseases associated with sodium
retention, such as congestive heart failure, cirrhotic liver
disease, and the nephrotic syndrome. In these clinical situ-
ations, resistance to diuretic therapy is often encountered
and larger doses of diuretics are sometimes needed to
achieve a natriuretic response. Several mechanisms are
involved in this drug-resistance, including changes in
renal haemodynamic or decreases in drug delivery into
the urine1331. One important factor, however, appears to
be an increased renal proximal reabsorption of solutes
mediated in part by the renal effect of the neurohormonal
responses. The common characteristic of these sodium-
retaining states resides in a decrease in effective arterial
blood volume which leads to an activation of the renin-
angiotensin system, vasopressin, prostaglandins and the
sympathetic nervous system'341. This hormonal response
causes renal vasoconstriction and favours sodium reab-
sorption in the proximal tubule. Hence, the efficacy of
diuretics is attenuated because sodium delivery to the sites
of action of thiazides, loop diuretics and potassium spar-
ing diuretics i.e. the late proximal and the distal tubules,
is reduced.
The use of diuretics in these diseases will sometimes
reinforce the neurohormal response and may favour the
development of undesirable effects. This is particularly
true when the disease has progressed to a point where
compensatory mechanisms are crucial for the mainten-
ance of blood pressure. Thus, in patients with severe
congestive heart failure (NYHA class III to IV), the
acute intravenous administration of furosemide has been
shown to increase plasma norepinephrine and vaso-
pressin levels and to raise plasma renin activity1'81. This
neurohormonal stimulation increases blood pressure and
peripheral vascular resistance and causes a transient
myocardial dysfunction. The performance of the heart
may therefore be transiently reduced by the use of loop
diuretics.
Dilutional hyponatremia is an important complication
of diuretic therapy which has been reported to predict
survival in patients with congestive heart failure. It is
often encountered in patients receiving large doses of loop
diuretics or a combination of thiazides and potassium-
sparing diuretics. In this situation, water is retained in
excess to sodium in response to the activation of vasopres-
sin and the renin-angiotensin and sympathetic nervous
systems. The role of the neurohormonal response in the
development of this complication is emphasized by the
fact that dilutional hyponatremia can be reversed within
a few days upon administration of an ACE inhibitor
which blocks the renin-angiotensin system and reduces
sympathetic drive and vasopressin
Prevention of the neurohormonal response to diuretics
There are several approaches to prevent the deleterious
effects of the neurohormonal response to diuretics. As
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Figure 2 Natriuretic effect of increasing doses of SCH 34826, an
inhibitor of atrial natriuretic peptide degradation, in eight healthy
salt-loaded volunteers. The cumulative sodium excretion expresses
the cumulative amount of sodium excreted after substraction of the
baseline elimination of sodium during the time of observation.
(Reproduced with permission1*71).
mentioned earlier, the activation of counter-regulatory
mechanisms depends on the severity of the salt and water
depletion induced by these agents. The use of low doses of
diuretics is therefore an effective and easy way to reduce
the hormone-mediated side effects of these agents. More-
over, it has been clearly demonstrated that thiazides or
potassium-sparing diuretics are effective antihypertensive
drugs at relatively low doses and that a dose increment
does not result in an increased efficacy'23'241.
Another effective approach is to block the activity of
the renin-angiotensin system. Many studies have shown
that angiotensin converting enzyme inhibitors, or angio-
tensin II antagonists, potentiate the blood pressure
lowering effect of diuretics by blunting the compensatory
rise in angiotensin II and aldosterone. For this reason,
the association of an ACE inhibitor with a diuretic has
become a useful combination in the treatment of hyper-
tension or congestive heart failure. It is important to note,
however, that this potentiation may be absent if blood
pressure is reduced to below the autoregulation capacity
of the kidneys, thereby leading to a fall in glomerular
filtration.
Calcium antagonists may also interfere with the activity
of the renin-angiotensin system. Indeed, nitrendipine has
been shown to blunt the rise in aldosterone secretion eli-
cited by the infusion of angiotensin II'371. Moreover, a
blunting of the angiotensin Il-induced pressor response
and aldosterone secretion has been demonstrated in
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hypertensive subjects during verapamil therapy*381. In
a recent study, nitrendipine has been shown to blunt
the bumetanide-induced increase in plasma aldosterone
without affecting the renin response in hypertensive
patients'39'. In a group of six patients, the natriuretic effect
of nitrendipine was additive to that of bumetanide but a
clear potentiation was not observed.
Since resistance to diuretics in sodium-retaining states
is due essentially to an increased renal proximal reabsorp-
tion of solutes, it might be expected that coadministration
of an agent inhibiting proximal reabsorption may restore
the sensitivity to diuretics. There are few, if any, studies
that have addressed this question. Brater has reported,
however, that administration of acetazolamide to some
furosemide-resistant patients caused a parallel upward
shift of the dose-response curve but not a normalisation of
the right-shifted curve133'.
In the future, it may become possible to use diuretics
that increase urinary sodium and water excretion and sim-
ultaneously reduce the activity of the renin-angiotensin
system. Atrial natriuretic peptides (ANP) have been
shown to promote sodium and water excretion and to
decrease plasma renin activity, thereby antagonizing the
renin-angiotensin system'9101. Since the early characteriz-
ation of the physiological and pharmacological effects of
atrial natriuretic peptides in animals and humans, several
drugs have been developed which reduce ANP degra-
dation by inhibiting its enzymatic metabolism via the neu-
tral endopeptidase140-421. These drugs lower blood pressure
in several animal models of hypertension and particularly
in the volume-dependent DOCA-hypertensive rat'431. In
normal subjects, neutral endopeptidase inhibitors
increase plasma or urinary ANP levels and exert natri-
uretic effects (Fig. 2)'44"461. However, their ability to reduce
blood pressure in patients with hypertension remains to
be demonstrated. Inhibitors of ANP degradation have
also been shown to increase renal sodium excretion in
patients with congestive heart failure or cirrhosis of the
liver147'48'. Thus, inhibition of ANP degradation may
become a very useful tool in the management of patients
with sodium retaining diseases. These drugs may have the
advantage of potentiating the effects of a 'natural' diuretic
i.e. ANP, which enhances sodium excretion without
activating major regulatory mechanisms.
Conclusion
The loss of sodium and fluid induced by the admin-
istration of diuretics triggers several neurohormonal
responses which have important clinical implications. The
regulatory mechanisms activated by diuretics, and in
particular the renin response, may limit the hypotensive
effects of these agents and contribute to the development
of side-effects such as hypokalaemia or metabolic acidosis.
To prevent the renin response or activation of vasopressin
or of the sympathetic nervous system, diuretics should be
used at lower doses or can be combined with drugs such as
converting enzyme inhibitors or perhaps calcium channel
blockers. The development of drugs able to enhance
sodium excretion and to reduce simultaneously the
activity of the renin angiotensin system might offer a new
alternative to treat hypertensive patients or patients with
sodium retaining states. In the future, this might perhaps
be achieved with neutral endopeptidase inhibitors which
interfere with the enzymatic degradation of ANP.
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